Alexander A. Vinogradov

Alexander A. Vinogradov

Auto-generated profile, based on publicly available information

Alexander A. Vinogradov

Department of Pharmacy and Pharmaceutical Sciences Faculty of Science National University of Singapore Singapore Singapore

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AVAlexander A. Vinogradov
Alexander A. Vinogradov
YYYizhen Yin
Yizhen Yin
HSHiroaki Suga
Hiroaki Suga


2 January 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SFSteven R. Fleming
Steven R. Fleming
TBTessa E. Bartges
Tessa E. Bartges
AVAlexander A. Vinogradov
Alexander A. Vinogradov
CKChristine L. Kirkpatrick
Christine L. Kirkpatrick
YGYuki Goto
Yuki Goto
ABAlbert A. Bowers
Albert A. Bowers

8 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAlexander A. Vinogradov
Alexander A. Vinogradov
MSMorito Shimomura
Morito Shimomura
YGYuki Goto
Yuki Goto
TOTaro Ozaki
Taro Ozaki
SAShumpei Asamizu
Shumpei Asamizu
HOHiroyasu Onaka
Hiroyasu Onaka
Lactazole A is a cryptic thiopeptide from Streptomyces lactacystinaeus, encoded by a compact 9.8 kb biosynthetic gene cluster. Here, we establish a platform for in vitro biosynthesis of lactazole A, referred to as the FIT-Laz system, via a combination of the flexible in vitro translation (FIT) system with recombinantly produced lactazole biosynthetic enzymes. Systematic dissection of lactazole biosynthesis reveals remarkable substrate tolerance of the biosynthetic enzymes and leads to the development of the minimal lactazole scaffold, a construct requiring only 6 post-translational modifications for macrocyclization. Efficient assembly of such minimal thiopeptides with FIT-Laz opens access to diverse lactazole analogs with 10 consecutive mutations, 14- to 62-membered macrocycles, and 18 amino acid-long tail regions, as well as to hybrid thiopeptides containing non-proteinogenic amino acids. This work suggests that the minimal lactazole scaffold is amenable to extensive bioengineering and opens possibilities to explore untapped chemical space of thiopeptides.

25 October 2022 in Journal of the American Chemical Society
Verified
Journal Article
Open access
AVAlexander A. Vinogradov
Alexander A. Vinogradov
YZYue Zhang
Yue Zhang
KHKeisuke Hamada
Keisuke Hamada
JCJun Shi Chang
Jun Shi Chang
COChikako Okada
Chikako Okada
HSHiroaki Suga
Hiroaki Suga
Bioengineering of ribosomally synthesized and post-translationally modified peptides (RiPPs) is an emerging approach to explore the diversity of pseudo-natural product structures for drug discovery purposes. However, despite the initial advances in this area, bioactivity reprogramming of multienzyme RiPP biosynthetic pathways remains a major challenge. Here, we report a platform for de novo discovery of functional thiopeptides based on reengineered biosynthesis of lactazole A, a RiPP natural product assembled by five biosynthetic enzymes. The platform combines in vitro biosynthesis of lactazole-like thiopeptides and mRNA display to prepare and screen large (≥1012) combinatorial libraries of pseudo-natural products. We demonstrate the utility of the developed protocols in an affinity selection against Traf2- and NCK-interacting kinase (TNIK), a protein involved in several cancers, which yielded a plethora of candidate thiopeptides. Of the 11 synthesized compounds, 9 had high affinities for the target kinase (best KD = 1.2 nM) and 10 inhibited its enzymatic activity (best Ki = 3 nM). X-ray structural analysis of the TNIK/thiopeptide interaction revealed the unique mode of substrate-competitive inhibition exhibited by two of the discovered compounds. The thiopeptides internalized to the cytosol of HEK293H cells as efficiently as the known cell-penetrating peptide Tat (4-6 μM). Accordingly, the most potent compound, TP15, inhibited TNIK in HCT116 cells. Altogether, our platform enables the exploration of pseudo-natural thiopeptides with favorable pharmacological properties in drug discovery applications.

26 May 2022 in ACS Central Science
Verified
Journal Article
Open access
AVAlexander A. Vinogradov
Alexander A. Vinogradov
JCJun Shi Chang
Jun Shi Chang
HOHiroyasu Onaka
Hiroyasu Onaka
YGYuki Goto
Yuki Goto
HSHiroaki Suga
Hiroaki Suga
Promiscuous post-translational modification (PTM) enzymes often display nonobvious substrate preferences by acting on diverse yet well-defined sets of peptides and/or proteins. Understanding of substrate fitness landscapes for PTM enzymes is important in many areas of contemporary science, including natural product biosynthesis, molecular biology, and biotechnology. Here, we report an integrated platform for accurate profiling of substrate preferences for PTM enzymes. The platform features (i) a combination of mRNA display with next-generation sequencing as an ultrahigh throughput technique for data acquisition and (ii) deep learning for data analysis. The high accuracy (>0.99 in each of two studies) of the resulting deep learning models enables comprehensive analysis of enzymatic substrate preferences. The models can quantify fitness across sequence space, map modification sites, and identify important amino acids in the substrate. To benchmark the platform, we performed profiling of a Ser dehydratase (LazBF) and a Cys/Ser cyclodehydratase (LazDEF), two enzymes from the lactazole biosynthesis pathway. In both studies, our results point to complex enzymatic preferences, which, particularly for LazBF, cannot be reduced to a set of simple rules. The ability of the constructed models to dissect such complexity suggests that the developed platform can facilitate a wider study of PTM enzymes.